Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Cipterbin (inetetamab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

3SBio

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + inetetamab Sensitive: C2 – Inclusion Criteria pertuzumab + inetetamab Sensitive : C2	pertuzumab + inetetamab Sensitive: C2 – Inclusion Criteria pertuzumab + inetetamab Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	inetetamab Sensitive: C2 – Inclusion Criteria inetetamab Sensitive : C2	inetetamab Sensitive: C2 – Inclusion Criteria inetetamab Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	camrelizumab + inetetamab Sensitive: C3 – Early Trials camrelizumab + inetetamab Sensitive : C3	camrelizumab + inetetamab Sensitive: C3 – Early Trials camrelizumab + inetetamab Sensitive : C3
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	sirolimus + inetetamab Sensitive: C4 – Case Studies sirolimus + inetetamab Sensitive : C4	sirolimus + inetetamab Sensitive: C4 – Case Studies sirolimus + inetetamab Sensitive : C4